The global immune checkpoint inhibitors market by Drug Class (Programmed Death Receptor-1 (PD-1) Inhibitors (Pembrolizumab (Keytruda), Nivolumab (Opdivo), Cemiplimab (Libtayo), Others (Spartalizumab), Programmed Death-Ligand 1 (PD-L1) Inhibitors (Atezolizumab (Tecentriq), Avelumab (Bavencio), Durvalumab (Imfinzi)), Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) Inhibitors (Ipilimumab (Yervoy)), Indoleamine-2,3-dioxygenase (IDO) Inhibitors, Lymphocyte-Activation Gene 3 Inhibitors)), By Cancer Type (Lung Cancer, Head & Neck Cancers, Skin Cancer (Melanoma and Merkel Cell Carcinoma), Blood Cancer (Lymphoma), Bladder Cancer (Urothelial Carcinoma), Renal/Kidney Cancer, Colorectal Cancer, Breast Cancer, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) was valued at US$ 10,543.8 million in 2017, and is projected to exhibit a CAGR of 11.8% over the forecast period (2018 – 2026).

Increasing prevalence of cancer is expected to boost the demand for immune checkpoint inhibitors. Also, innovative drug launches along with robust pipeline is expected to boost the global immune checkpoint inhibitors market growth over the forecast period. Major manufacturers are investing into R&D to develop immune-checkpoint therapies by understanding tumor functions and ways to combat them. Manufacturers are focusing on upgrading available immune checkpoint inhibitors as well as developing new immune checkpoint inhibitors for cancer treatment. For instance, AstraZeneca’s Durvalumab (Imfinzi) was approved in 2017, as immune checkpoint inhibitor, which blocks interaction of PD-L1 with PD-1 and CD80. In December 2017, Bristol-Myers Squibb received approval for Nivolumab (Opdivo) in adjuvant treatment of melanoma. In March 2017, Avelumab (Bavencio), jointly developed by EMD Serono, and Pfizer, Inc. received U.S. Food & Drug Administration (FDA) approval for the treatment of metastatic merkel cell carcinoma. In 2017, the U.S. FDA granted accelerated approval to immunotherapy product- TECENTRIQ (atezolizumab) for the treatment of patients with locally advanced or metastatic urothelial carcinoma (mUC).

Browse 46 Market Data Tables and 41 Figures spread through 238 Pages and in-depth TOC on Global Immune Checkpoint Inhibitors Market by Drug Class (Programmed Death Receptor-1 (PD-1) Inhibitors (Pembrolizumab (Keytruda), Nivolumab (Opdivo), Cemiplimab (Libtayo), Others (Spartalizumab), Programmed Death-Ligand 1 (PD-L1) Inhibitors (Atezolizumab (Tecentriq), Avelumab (Bavencio), Durvalumab (Imfinzi)), Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) Inhibitors (Ipilimumab (Yervoy)), Indoleamine-2,3-dioxygenase (IDO) Inhibitors, Lymphocyte-Activation Gene 3 Inhibitors)), By Cancer Type (Lung Cancer, Head & Neck Cancers, Skin Cancer (Melanoma and Merkel Cell Carcinoma), Blood Cancer (Lymphoma), Bladder Cancer (Urothelial Carcinoma), Renal/Kidney Cancer, Colorectal Cancer, Breast Cancer, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies),  and region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) - Global Forecast to 2025

To know the latest trends and insights prevalent in the Global Immune Checkpoint Inhibitors Market, click the link below:

https://www.coherentmarketinsights.com/market-insight/immune-checkpoint-inhibitors-market-2560

Research and development by leading as well as small and mid-sized players in immune checkpoint inhibitors market is expected to support global immune checkpoint inhibitors market growth. For instance, Oncolytics Biotech, Inc. announced research collaboration with the Keck School of Medicine of University of Southern California (USC), in order to develop a combination therapy of Reolycin (Oncolytics Biotech’s product), Keytruda, Velcade, and dexamethasone for the treatment of multiple myeloma in May 2018. Furthermore, in January 2018, Keytruda, developed by Merck & Co. reported slow liver cancer progression in Phase 2 trial. Immuno-oncology combination therapies are also under research for various cancer indications.

In January 2018, the U.S. Food & Drug Administration (FDA) granted breakthrough therapy status to Lenvima-Keytruda combo for advanced kidney cancer. Furthermore, in February 2018, Opdivo-Yervoy combination therapy showed delayed disease progression in patients with advanced non-small cell lung cancer. Moreover, Genentech combination therapy Tecentriq and Avastin delayed kidney cancer progression in Phase III trials in December 2017. AstraZeneca Plc’s Imfinzi (Durvalumab) showed delayed non-small cell lung cancer progression in Phase III trials in November 2017.

Key Takeaways of the Global Immune Checkpoint Inhibitors Market:

  • The global immune checkpoint inhibitors market is expected to exhibit a CAGR of 8% over the forecast period. This is attributed to presence of several leading manufacturers who are focusing on introducing innovative therapies through extensive research and development such as Bristol Myers Squibb, Novartis, and Pfizer, Inc.
  • Biopharmaceutical companies are developing a robust pipeline of immune-checkpoint inhibitor combination therapies due to their increasing demand. The U.S. Food & Drug Administration (FDA) has approved a number of immune checkpoint inhibitors including Yervoy (anti-CTLA-4), Opdivo and Keytruda (anti-PD1) and Tecentriq (anti-PD-L1).
  • Immuno-checkpoint inhibitor combination therapies are expected to change the market scenario over the forecast period, owing to positive results in the clinical trials
  • Research partnerships and collaborations to develop new drugs by various market players is supporting growth of the market, as competitors are striving to gain competitive edge in the market
  • Major players operating in the global immune checkpoint inhibitors market include Bristol-Myers Squibb Company, Merck & Co., Inc., F. Hoffmann-La Roche AG, AstraZeneca Plc., Novartis International AG, ImmunOs Therapeutics AG, Immutep Ltd., NewLink Genetics Corporation, Ono Pharmaceutical Co., Ltd., and Pfizer, Inc.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner